EA201291217A1 - ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ - Google Patents

ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ

Info

Publication number
EA201291217A1
EA201291217A1 EA201291217A EA201291217A EA201291217A1 EA 201291217 A1 EA201291217 A1 EA 201291217A1 EA 201291217 A EA201291217 A EA 201291217A EA 201291217 A EA201291217 A EA 201291217A EA 201291217 A1 EA201291217 A1 EA 201291217A1
Authority
EA
Eurasian Patent Office
Prior art keywords
thienylmetylbenzene
nzgt
glukopiranosil
inhibitors
pharmaceutical compositions
Prior art date
Application number
EA201291217A
Other languages
English (en)
Other versions
EA022365B1 (ru
Inventor
Венхуа Ванг
Тодд Аутвин
Томас К. Джозеф
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44260412&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291217(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201291217A1 publication Critical patent/EA201291217A1/ru
Publication of EA022365B1 publication Critical patent/EA022365B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Настоящее изобретение относится к композициям, включающим в себя соединения формулы (I)или их пролекарство или фармацевтически приемлемую соль.
EA201291217A 2010-05-11 2011-05-11 Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг EA022365B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33349510P 2010-05-11 2010-05-11
PCT/US2011/036038 WO2011143296A1 (en) 2010-05-11 2011-05-11 Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt

Publications (2)

Publication Number Publication Date
EA201291217A1 true EA201291217A1 (ru) 2013-09-30
EA022365B1 EA022365B1 (ru) 2015-12-30

Family

ID=44260412

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291217A EA022365B1 (ru) 2010-05-11 2011-05-11 Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг

Country Status (40)

Country Link
US (4) US20120115799A1 (ru)
EP (1) EP2568988B1 (ru)
JP (2) JP6227406B2 (ru)
KR (1) KR101931209B1 (ru)
CN (2) CN102883726A (ru)
AR (1) AR081036A1 (ru)
AU (3) AU2011250909A1 (ru)
BR (1) BR112012028857B1 (ru)
CA (1) CA2799204C (ru)
CL (1) CL2012003162A1 (ru)
CO (1) CO6630184A2 (ru)
CR (1) CR20120626A (ru)
CY (1) CY1118093T1 (ru)
DK (1) DK2568988T3 (ru)
EA (1) EA022365B1 (ru)
EC (1) ECSP12012290A (ru)
ES (1) ES2596291T3 (ru)
GT (1) GT201200303A (ru)
HK (1) HK1259250A1 (ru)
HR (1) HRP20161231T1 (ru)
HU (1) HUE029853T2 (ru)
IL (1) IL222858B (ru)
JO (1) JO3577B1 (ru)
LT (1) LT2568988T (ru)
ME (1) ME02531B (ru)
MX (1) MX339570B (ru)
MY (1) MY187718A (ru)
NI (1) NI201200168A (ru)
NZ (1) NZ703128A (ru)
PE (1) PE20130227A1 (ru)
PL (1) PL2568988T3 (ru)
PT (1) PT2568988T (ru)
RS (1) RS55202B1 (ru)
SG (2) SG10201506114UA (ru)
SI (1) SI2568988T1 (ru)
SM (1) SMT201600338B (ru)
TW (1) TWI599360B (ru)
UA (1) UA110207C2 (ru)
UY (1) UY33380A (ru)
WO (1) WO2011143296A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2200606T (pt) * 2007-09-10 2017-12-13 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010270202B2 (en) 2009-07-10 2014-04-24 Janssen Pharmaceutica Nv Crystallisation process for 1-(beta-D-glucopyranosyl)-4-methyl-3- [5-(4-fluorophenyl)-2-thienylmethyl] benzene
RS55909B1 (sr) * 2009-10-14 2017-09-29 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
CN102883726A (zh) 2010-05-11 2013-01-16 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物作为SGLT抑制剂的药物制剂
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CN103641822B (zh) * 2013-10-21 2016-06-08 江苏奥赛康药业股份有限公司 一种卡格列净化合物及其药物组合物
EP2990029A1 (en) 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
WO2019046659A1 (en) * 2017-08-30 2019-03-07 First Fruits Business Ministry, Llc COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
CN108078945B (zh) * 2018-01-12 2020-09-11 杭州中美华东制药有限公司 卡格列净药物组合物
US11857559B2 (en) 2018-09-10 2024-01-02 Aurobindo Pharma Ltd. Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof
CN111773194B (zh) * 2019-04-04 2023-06-30 常州恒邦药业有限公司 一种卡格列净片剂及其制备方法
CN116785268A (zh) * 2022-03-14 2023-09-22 江苏万邦生化医药集团有限责任公司 一种sglt-2抑制剂的药物组合物

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US4160861A (en) 1977-10-03 1979-07-10 Merck & Co., Inc. Method for the separation of antibiotic macrolides
US4584369A (en) 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
JPS5939889A (ja) 1982-08-30 1984-03-05 Noguchi Kenkyusho ２，４，６↓−トリ↓−０↓−アセチル↓−３↓−デオキシ↓−ヘキソノ↓−１，５↓−ラクトンの製造方法
JP2544609B2 (ja) 1986-10-07 1996-10-16 和光純薬工業株式会社 Ｔｃｎｑ錯体
US4863957A (en) 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
CA1327013C (en) 1988-06-23 1994-02-15 Peter Rex Brawn Cosmetic composition
JP2786896B2 (ja) 1988-08-19 1998-08-13 ワーナー―ランバート・コンパニー 置換されたジヒドロイソキノリノンおよび関連化合物
ATE123237T1 (de) * 1990-08-24 1995-06-15 Spirig Ag Verfahren zur herstellung von pellets.
JPH04253974A (ja) 1991-02-05 1992-09-09 Ishihara Sangyo Kaisha Ltd スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤
EP0517969A1 (en) 1991-06-10 1992-12-16 AUSIMONT S.p.A. Process for increasing the bleaching efficiency of an inorganic persalt or of hydrogen peroxide
US5149838A (en) 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
US5610294A (en) 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
ZA927272B (en) 1991-10-29 1994-03-23 Du Pont Herbicidal triazolecarboxamides
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
US5334225A (en) 1992-07-15 1994-08-02 Kao Corporation Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5731292A (en) 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
DE4243279A1 (de) 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
US6297363B1 (en) 1993-02-12 2001-10-02 Nomura Co., Ltd. Glycoside indoles
JP3342727B2 (ja) 1993-03-01 2002-11-11 株式会社小松製作所 制振鋼板の曲げ加工方法および曲げ加工装置
JP3187611B2 (ja) 1993-05-17 2001-07-11 キヤノン株式会社 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
JPH07242526A (ja) 1994-03-03 1995-09-19 Sogo Yatsukou Kk 化粧料
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
EP0732921A4 (en) 1994-09-30 1998-09-02 Ohio State Res Found C-GLYCOSIDANOLOGIST OF N- (4-HYDROXYPHENYL) RETINAMIDE-O-GLUCURONIDE
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
JP2002500618A (ja) 1995-10-31 2002-01-08 イーライ・リリー・アンド・カンパニー 抗血栓性ジアミン
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
JPH09263549A (ja) 1996-01-25 1997-10-07 Fujisawa Pharmaceut Co Ltd ベンゼン誘導体の製造法
IL121525A0 (en) 1996-08-26 1998-02-08 Tanabe Seiyaku Co Process for preparing optically active benzothiazepine compound and intermediate therefor
ES2176600T3 (es) 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
WO1998042347A1 (en) 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing a phosphorylamide and an ayntibiotic
CA2320900C (en) 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
JP2002518364A (ja) 1998-06-18 2002-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 有機チタネートおよびグリニャール試薬を用いてカルボキサミドを対称および非対称二置換する方法
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
JP2000034239A (ja) 1998-07-16 2000-02-02 Asahi Glass Co Ltd トリフルオロメチル化芳香族化合物の製造方法
JP3857429B2 (ja) 1998-07-17 2006-12-13 ポーラ化成工業株式会社 含硫黄抗真菌剤
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
CN1325385A (zh) 1998-11-09 2001-12-05 詹姆斯·布莱克基金有限公司 胃泌素和缩胆囊素受体配体
EA011633B1 (ru) 1998-11-12 2009-04-28 Смитклайн Бичам Плс Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ATE390140T1 (de) 1999-11-03 2008-04-15 Bristol Myers Squibb Co Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP3450810B2 (ja) 2000-01-31 2003-09-29 キヤノン株式会社 脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびセルロースの再資源化方法
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
MXPA02008627A (es) 2000-03-03 2003-02-24 Pfizer Prod Inc Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos.
TR200202200T2 (tr) 2000-03-17 2002-12-23 Kissei Pharmaceutical Co., Ltd. Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler.
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
GB0011098D0 (en) 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
EP1172362A1 (de) 2000-07-11 2002-01-16 Basf Aktiengesellschaft Azadioxacycloalkene und ihre Verwendung zur Bekämpfung von Schadpilzen und tierischen Schädlingen
KR100426030B1 (ko) 2000-07-22 2004-04-03 (주) 한켐 락톤계 당화합물에서의 키랄성 전환방법
US6784167B2 (en) 2000-09-29 2004-08-31 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-II inhibitors
EP1338603B1 (en) 2000-11-02 2010-01-20 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
JP2002167430A (ja) 2000-12-01 2002-06-11 Canon Inc 脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびデンプンの資源化方法
US6476352B2 (en) 2000-12-18 2002-11-05 General Electric Company Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor
CA2432145C (en) 2000-12-28 2010-07-13 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and use thereof in medicines
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
JP4147111B2 (ja) 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体およびその医薬用途
WO2002070020A2 (en) 2001-03-02 2002-09-12 University Of Western Ontario Polymer precursors of radiolabeled compounds, and methods of making and using the same
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
JP4292570B2 (ja) 2001-04-27 2009-07-08 味の素株式会社 Ｎ−置換ピラゾール−ｏ−グリコシド誘導体及びそれらを含有する糖尿病治療薬
GB0112122D0 (en) 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
WO2003000712A1 (fr) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
JPWO2003011880A1 (ja) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US20030191121A1 (en) 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
DE60208809T2 (de) 2001-10-24 2006-11-02 Michael Warrington Burton Enzymsubstrate zum Nachweis der ß-D-Ribofuranosidase-Aktivität
CN1705654A (zh) 2001-11-08 2005-12-07 塞普拉科公司 使用对映体富集的西酞普兰去甲基和二去甲基代谢产物治疗抑郁症以及其它中枢神经病症的方法
WO2003043621A1 (en) 2001-11-16 2003-05-30 Cutanix Corporation Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
JP2003238417A (ja) 2002-02-18 2003-08-27 Nippon Shoyaku Kenkyusho:Kk フロレチン配糖体の安定化組成物、該安定化組成物を含有する糖尿病予防・治療剤、および保健食品
US6617313B1 (en) 2002-03-13 2003-09-09 Council Of Scientific And Industrial Research Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en) 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
JP2003313168A (ja) 2002-04-18 2003-11-06 Kirin Brewery Co Ltd Ｂｃｌ−２阻害活性を有する化合物およびその化合物のスクリーニング方法
JP4523775B2 (ja) 2002-04-18 2010-08-11 アストラゼネカ・アクチエボラーグ 複素環化合物
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
PL375298A1 (en) 2002-08-09 2005-11-28 Taisho Pharmaceutical Co, Ltd. Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides
AU2003262262A1 (en) 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
WO2004032845A2 (en) 2002-10-07 2004-04-22 Encore Pharmaceuticals, Inc. R-nsaid esters and their use
IN192749B (ru) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
KR20050090437A (ko) 2003-01-03 2005-09-13 브리스톨-마이어스 스큅 컴퍼니 Ｃ-아릴 글루코시드 ｓｇｌｔ２ 억제제의 제조 방법
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
WO2004076470A2 (en) 2003-02-27 2004-09-10 Bristol-Myers Squibb Company A non-cryogenic process for forming glycosides
BRPI0408140B8 (pt) 2003-03-14 2018-12-11 Astellas Pharma Inc derivado de c-glicosídeo ou seu sal, composição farmacêutica e uso do derivado de c-glicosídeo ou seu sal
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
ATE541854T1 (de) 2003-06-20 2012-02-15 Kissei Pharmaceutical Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung
BRPI0412257A (pt) 2003-07-23 2006-10-03 Synta Pharmaceuticals Corp compostos para inflamação e usos imuno-relacionados
EA009768B1 (ru) 2003-08-01 2008-04-28 Янссен Фармацевтика Нв Замещенные конденсированные гетероциклические с-гликозиды
TW200526678A (en) 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
WO2005011592A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-o-glucosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
AU2004261663A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
KR100778988B1 (ko) 2003-08-01 2007-11-28 다나베 미츠비시 세이야꾸 가부시키가이샤 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
WO2005058845A2 (en) 2003-12-19 2005-06-30 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
JP5017103B2 (ja) 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1773800A1 (de) 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
US20090124702A1 (en) 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
AR053329A1 (es) 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
WO2006089872A1 (en) 2005-02-23 2006-08-31 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
EP1874787B1 (en) 2005-04-15 2009-12-30 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
JP2007023099A (ja) 2005-07-13 2007-02-01 Yokohama Rubber Co Ltd:The ノルボルネン系樹脂用１液型ウレタン接着剤組成物ならびにノルボルネン系樹脂用弾性接着剤およびその使用方法
ES2346347T3 (es) 2005-07-27 2010-10-14 Boehringer Ingelheim International Gmbh Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
EP1924571B1 (en) 2005-08-30 2010-10-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
CN101057835A (zh) 2005-09-26 2007-10-24 刘凤鸣 二甲双胍格列本脲的缓释制剂
EP1983971A4 (en) 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp SUBSTITUTED AROMATIC COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
WO2008020011A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
US7858587B2 (en) 2006-09-21 2010-12-28 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
KR100812538B1 (ko) 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
JP2010508371A (ja) 2006-11-06 2010-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
CA3007700A1 (en) 2006-11-09 2008-05-15 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
CN101611032B (zh) 2006-12-04 2012-07-18 詹森药业有限公司 作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物
EP1956023A1 (en) 2007-02-06 2008-08-13 Lonza Ag Method for lithium exchange reactions
CA2681092A1 (en) 2007-03-15 2008-09-18 Nectid, Inc. Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
US20090047514A1 (en) 2007-08-15 2009-02-19 Allen David P Thermal Activated Pressure Sensitive Adhesive and Method for Producing the Same and Product therewith
CL2008002425A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
PT2200606T (pt) 2007-09-10 2017-12-13 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR101512386B1 (ko) 2008-04-08 2015-04-17 제이더블유중외제약 주식회사 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
CA2730734C (en) 2008-07-15 2017-04-25 Theracos, Inc. Deuterated 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene compounds having sodium glucose cotransporter inhibitory activity
KR101654231B1 (ko) 2008-08-22 2016-09-05 테라코스 서브, 엘엘씨 Ｓｇｌｔ２ 억제제의 제조방법
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
LT2395983T (lt) 2009-02-13 2020-07-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
UA110322C2 (uk) * 2009-04-24 2015-12-25 Iceutica Pty Ltd Спосіб одержання композиції наночастинок біологічно активного матеріалу з високою об'ємною часткою
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
RS55909B1 (sr) 2009-10-14 2017-09-29 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
CN102883726A (zh) 2010-05-11 2013-01-16 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物作为SGLT抑制剂的药物制剂
CA2804506C (en) * 2010-07-06 2018-08-21 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes

Also Published As

Publication number Publication date
AU2011250909A1 (en) 2012-11-29
AU2017210661A1 (en) 2017-08-24
HRP20161231T1 (hr) 2016-11-04
JO3577B1 (ar) 2020-07-05
KR20130062947A (ko) 2013-06-13
NI201200168A (es) 2013-01-29
JP2016147866A (ja) 2016-08-18
PL2568988T3 (pl) 2017-02-28
MX339570B (es) 2016-05-31
LT2568988T (lt) 2016-09-12
NZ703128A (en) 2016-04-29
ME02531B (me) 2017-02-20
HK1259250A1 (zh) 2019-11-29
AR081036A1 (es) 2012-05-30
HUE029853T2 (en) 2017-04-28
EA022365B1 (ru) 2015-12-30
BR112012028857B1 (pt) 2021-02-09
ECSP12012290A (es) 2012-12-28
CR20120626A (es) 2013-07-03
CA2799204A1 (en) 2011-11-17
UA110207C2 (en) 2015-12-10
CO6630184A2 (es) 2013-03-01
SMT201600338B (it) 2016-11-10
JP6227406B2 (ja) 2017-11-08
CN102883726A (zh) 2013-01-16
TW201206447A (en) 2012-02-16
IL222858A0 (en) 2012-12-31
US10617668B2 (en) 2020-04-14
PE20130227A1 (es) 2013-02-27
DK2568988T3 (en) 2016-08-22
CN108354930A (zh) 2018-08-03
US20170112806A1 (en) 2017-04-27
AU2015207823A1 (en) 2015-08-20
IL222858B (en) 2018-03-29
US20150005244A1 (en) 2015-01-01
WO2011143296A1 (en) 2011-11-17
UY33380A (es) 2011-12-01
ES2596291T3 (es) 2017-01-05
PT2568988T (pt) 2016-09-22
CY1118093T1 (el) 2017-06-28
SG185525A1 (en) 2012-12-28
EP2568988B1 (en) 2016-07-13
AU2017210661B2 (en) 2019-07-18
MX2012013090A (es) 2013-01-18
BR112012028857A2 (pt) 2016-07-26
SI2568988T1 (sl) 2016-10-28
TWI599360B (zh) 2017-09-21
US20130338087A1 (en) 2013-12-19
GT201200303A (es) 2014-04-29
MY187718A (en) 2021-10-14
SG10201506114UA (en) 2015-09-29
KR101931209B1 (ko) 2018-12-20
JP2013526534A (ja) 2013-06-24
CA2799204C (en) 2018-11-06
EP2568988A1 (en) 2013-03-20
US20120115799A1 (en) 2012-05-10
RS55202B1 (sr) 2017-01-31
CL2012003162A1 (es) 2013-06-07

Similar Documents

Publication Publication Date Title
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
IN2014CN04530A (ru)
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
MY165087A (en) Neprilysin inhibitors
MX342212B (es) Inhibidores de neprilisina.
MD20140136A2 (ru) Ингибиторы вируса гепатита С
UA111770C2 (uk) Інгібітори бромдомену
EA201401351A1 (ru) Производные бензимидазол-пролина
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201101026A1 (ru) Ингибиторы бета-секретазы
PH12015500260A1 (en) Neprilysin inhibitors
EA201270216A1 (ru) Фармацевтический состав
MX2013006802A (es) Inhibidores de neprilisina.
MY170935A (en) Neprilysin inhibitors
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
EA201501163A1 (ru) Модуляторы рецептора cxcr7
UA107455C2 (ru) Производные индола как противораковые агенты